Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2).
about
Molecular Targeted Therapies of Aggressive Thyroid CancerPhosphorylation of protocadherin proteins by the receptor tyrosine kinase RetComputational modeling of structurally conserved cancer mutations in the RET and MET kinases: the impact on protein structure, dynamics, and stability.Thyroid cancer: current molecular perspectives.Immune response in thyroid cancer: widening the boundaries.BAY 43-9006 inhibition of oncogenic RET mutants.The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.Src inhibitors in suppression of papillary thyroid carcinoma growth.The RET proto-oncogene: a molecular therapeutic target in thyroid cancer.New perspectives on the treatment of differentiated thyroid cancer.Pyrazolo[3,4-d]pyrimidines as inhibitor of anti-coagulation and inflammation activities of phospholipase A 2 : insight from molecular docking studies.Thyroid carcinoma: molecular pathways and therapeutic targetsWhat is New on Thyroid Cancer BiomarkersRET TKI: potential role in thyroid cancers.Sorafenib and thyroid cancer.Thyroid Cancer: Role of RET and Beyond.CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation.4-Substituted-1-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives: design, synthesis, antitumor and EGFR tyrosine kinase inhibitory activity.GM1 ganglioside enhances Ret signaling in striatum.Growth inhibition of medullary thyroid carcinoma cells by pyrazolo-pyrimidine derivates.Personalization of targeted therapy in advanced thyroid cancer.Pyrazolo[3,4-d]pyrimidines as novel inhibitors of O-acetyl-L-serine sulfhydrylase of Entamoeba histolytica: an in silico study.New targeted molecular therapies for dedifferentiated thyroid cancer.Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma.Identification of RET kinase inhibitors as potential new treatment for sporadic and inherited thyroid cancer.Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer.Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis
P2860
Q26774734-5665F04D-C76E-4930-BAEF-8E3913EE62D9Q28287438-9A6F432A-85D9-4227-93BB-49ACD71FDB12Q30374663-A8A896B7-AF63-4311-AED1-DF8B2D33684EQ33760910-81DD971D-C3C0-4437-97E8-012C34DC7D5EQ34310495-62F217D0-A64A-4490-A1B6-A7423163D500Q34565246-C5A74BA1-EC6E-4DFF-B1A7-8FA47D0654B2Q35103009-0F94AD61-ABED-480E-80D1-027A15DC6B33Q35457965-D74C213F-43B7-4AD4-978D-F7EF15F6DDBDQ36072495-7EB69E39-D759-4FEC-A40A-56D738437C33Q36904500-B210F3AE-962A-45E6-862F-B12B13E533AFQ36946302-D822FA7C-BC5F-4483-9EB0-1CD3909136E0Q37147768-4AACF6F9-F2E1-44DD-B13B-246671000C9DQ37207279-A4DFCF79-BEE1-4FEC-BD73-086D9DA2D406Q37979656-0B6DDFB2-9024-42B4-8437-5088529E01E6Q38118647-4FC37BF2-562F-4EAD-9136-A6FE26F2EA29Q38208316-B54EDB3D-8310-407F-A069-56A5B9BBEA2AQ38842666-3EFE02F2-C231-40B8-B812-BA452E3A93F4Q38947588-0915FCFD-04C2-485C-BEA4-B1C2C83F5212Q38995699-977D06A2-92CA-42DC-B2CA-262CBB93253BQ40036483-0991DFCB-26FA-4EC8-848F-0B7D15E26B8FQ40922523-FADAB987-7ED7-4CF6-B894-337E8E7BF04DQ42175417-E3338884-9007-45F2-AD8D-EA014F0C13E5Q42734670-0ADD818A-2BE3-4954-A90C-3BF1B8AFAA01Q44968984-DFF26F36-7F70-4629-9370-81CDF4E119F8Q45252043-2E9F684D-C536-4739-B33C-2D124E3FDFE9Q47601932-319BEAD2-DF94-4488-B7AF-5B4B623BED04Q50085302-AF0622F5-0807-4A90-BF55-1BA720615FB9Q58053853-78176C79-3316-4A6F-82E8-C3CD488D7F1B
P2860
Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2).
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Efficient inhibition of RET/pa ...... razolo[3,4-d]pyrimidine (PP2).
@ast
Efficient inhibition of RET/pa ...... razolo[3,4-d]pyrimidine (PP2).
@en
Efficient inhibition of RET/pa ...... razolo[3,4-d]pyrimidine (PP2).
@nl
type
label
Efficient inhibition of RET/pa ...... razolo[3,4-d]pyrimidine (PP2).
@ast
Efficient inhibition of RET/pa ...... razolo[3,4-d]pyrimidine (PP2).
@en
Efficient inhibition of RET/pa ...... razolo[3,4-d]pyrimidine (PP2).
@nl
prefLabel
Efficient inhibition of RET/pa ...... razolo[3,4-d]pyrimidine (PP2).
@ast
Efficient inhibition of RET/pa ...... razolo[3,4-d]pyrimidine (PP2).
@en
Efficient inhibition of RET/pa ...... razolo[3,4-d]pyrimidine (PP2).
@nl
P2093
P50
P356
P1476
Efficient inhibition of RET/pa ...... yrazolo[3,4-d]pyrimidine (PP2)
@en
P2093
Donata Vitagliano
Francesca Carlomagno
Massimo Santoro
Teresa Guida
P304
P356
10.1210/JC.2002-021278
P407
P577
2003-04-01T00:00:00Z